ArticleFrontiers in oncology2023
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab.
Amalia Varo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this paperpooled itcites it